Team Blitz India
WASHINGTON: India has the potential to increase global clinical trials in the country by five times in the coming years, a report has said, with experts highlighting the significant opportunities for biopharma companies to leverage India’s rich diversity and robust healthcare infrastructure to develop innovative treatments.
The joint report by the USA India Chamber of Commerce & PwC India titled, “Clinical Trial opportunities in India” released at the virtual edition of the 17th annual BioPharma & Healthcare Summit 2023 on May 3 in Boston also indicates that through several key drivers, India is emerging as a favourable destination to conduct clinical trials.
According to the report, the private sector is a well-suited channel for the top biopharma to conduct more efficient clinical trials with easier and faster access to investigators and patients.
Indian states with high disease prevalence (e.g. cancer) also have the most number of Tier-1 cities, with advanced medical infrastructure and availability of investigators. Targeting these states can provide biopharma companies with faster access to patients, sites, and investigators.
India has an overall clinical trial participation of three per cent but contributes upwards of 15 per cent to the global burden of most high prevalent diseases (e.g. respiratory infections, cardiovascular, diabetes, cervical cancer), representing an untapped potential for top pharma, the report said.
Dr Naresh Trehan, CMD Medanta and USAIC advisory board member believes that India’s healthcare landscape is poised for transformation, with its vast and diverse population in need of innovative solutions to address a range of health challenges.
